CSS
MGX icon

Cubist Systematic Strategies’s Metagenomi Therapeutics MGX Stock Holding History

Cubist Systematic Strategies’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$17.7K Buy
7,461
+4,348
+140% +$8.82K ﹤0.01% 2904
2025
Q2 		$4.61K Buy
+3,113
New +$4.88K ﹤0.01% 2854
2024
Q4 		– Sell
-3,237
Closed -$7.02K – 3654
2024
Q3 		$7.02K Buy
+3,237
New +$11.2K ﹤0.01% 2862

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Cubist Systematic Strategies's MGX Position: Q3 2025 in Review

Cubist Systematic Strategies increased its Metagenomi Therapeutics (MGX) stake by 140% in Q3 2025, buying an estimated $8.82K and bringing the position to 7,461 shares worth $17.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2904.

Cubist Systematic Strategies first reported a position in MGX in Q3 2024 and has held it in 3 quarters since. 58 funds tracked by Wall St. Rank hold MGX as of Q3 2025.

  • Cubist Systematic Strategies held 7,461 shares of Metagenomi Therapeutics worth $17.7K as of Q3 2025.
  • Cubist Systematic Strategies bought 4,348 Metagenomi Therapeutics shares in Q3 2025, an estimated $8.82K.
  • Metagenomi Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2904 holding.
  • Cubist Systematic Strategies first reported a position in Metagenomi Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • 58 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.